PI3 Kinase p110 Beta Monoklonaler Antikörper
PI3 Kinase p110 Beta Monoklonal Antikörper für WB, IHC, IF/ICC, ELISA
Wirt / Isotyp
Maus / IgG1
Getestete Reaktivität
human, Ratte und mehr (1)
Anwendung
WB, IHC, IF/ICC, ELISA
Konjugation
Unkonjugiert
CloneNo.
1B2A1
Kat-Nr. : 67121-1-Ig
Synonyme
Geprüfte Anwendungen
| Erfolgreiche Detektion in WB | HEK-293-Zellen, HeLa-Zellen, MCF-7-Zellen, PC-12-Zellen, SH-SY5Y-Zellen |
| Erfolgreiche Detektion in IHC | humanes Lungenkarzinomgewebe, humanes Zervixkarzinomgewebe, humanes Kolonkarzinomgewebe Hinweis: Antigendemaskierung mit TE-Puffer pH 9,0 empfohlen. (*) Wahlweise kann die Antigendemaskierung auch mit Citratpuffer pH 6,0 erfolgen. |
| Erfolgreiche Detektion in IF/ICC | HeLa-Zellen |
Empfohlene Verdünnung
| Anwendung | Verdünnung |
|---|---|
| Western Blot (WB) | WB : 1:2000-1:10000 |
| Immunhistochemie (IHC) | IHC : 1:150-1:600 |
| Immunfluoreszenz (IF)/ICC | IF/ICC : 1:1000-1:4000 |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, check data in validation data gallery | |
Veröffentlichte Anwendungen
| WB | See 27 publications below |
| IHC | See 5 publications below |
Produktinformation
67121-1-Ig bindet in WB, IHC, IF/ICC, ELISA PI3 Kinase p110 Beta und zeigt Reaktivität mit human, Ratten
| Getestete Reaktivität | human, Ratte |
| In Publikationen genannte Reaktivität | human, Maus, Ratte |
| Wirt / Isotyp | Maus / IgG1 |
| Klonalität | Monoklonal |
| Typ | Antikörper |
| Immunogen | PI3 Kinase p110 Beta fusion protein Ag17505 |
| Vollständiger Name | phosphoinositide-3-kinase, catalytic, beta polypeptide |
| Berechnetes Molekulargewicht | 1070 aa, 123 kDa |
| Beobachtetes Molekulargewicht | 120-130 kDa |
| GenBank-Zugangsnummer | BC114432 |
| Gene symbol | PI3 Kinase p110 Beta |
| Gene ID (NCBI) | 5291 |
| Konjugation | Unkonjugiert |
| Form | Liquid |
| Reinigungsmethode | Protein-G-Reinigung |
| Lagerungspuffer | PBS with 0.02% sodium azide and 50% glycerol |
| Lagerungsbedingungen | Bei -20°C lagern. Nach dem Versand ein Jahr lang stabil Aliquotieren ist bei -20oC Lagerung nicht notwendig. 20ul Größen enthalten 0,1% BSA. |
Hintergrundinformationen
PIK3CB(phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform) is also named as PIK3C1, PI3K-beta, p110beta. The gene encodes a 1070 amino acid protein which belongs to the PI3/PI4-kinase family. Phosphoinositide 3-kinases (PI3Ks) have been implicated as participants in signaling pathways regulating cell growth by virtue of their activation in response to various mitogenic stimuli. The class I PI3 kinases are heterodimers composed of 110 kDa catalytic subunits that associate with regulatory adaptor proteins. Four class I catalytic subunits have been identified, PIK3CA (p110α), PIK3CB (p110β), PIK3CD (p110δ) and PIK3CG (p110γ)(PMID:19177002).
Protokolle
| PRODUKTSPEZIFISCHE PROTOKOLLE | |
|---|---|
| WB protocol for PI3 Kinase p110 Beta antibody 67121-1-Ig | Protokoll herunterladen |
| IHC protocol for PI3 Kinase p110 Beta antibody 67121-1-Ig | Protokoll herunterladenl |
| IF protocol for PI3 Kinase p110 Beta antibody 67121-1-Ig | Protokoll herunterladen |
| STANDARD-PROTOKOLLE | |
|---|---|
| Klicken Sie hier, um unsere Standardprotokolle anzuzeigen |
Publikationen
| Species | Application | Title |
|---|---|---|
Nat Metab Maternal exercise prevents metabolic disorders in offspring mice through SERPINA3C | ||
J Med Chem Discovery of Novel Phosphoinositide-3-Kinase α Inhibitors with High Selectivity, Excellent Bioavailability, and Long-Acting Efficacy for Gastric Cancer. | ||
J Ethnopharmacol Antitumor mechanism of kangliu pill on gliomas in mice through PI3K-Akt signaling pathway | ||
Front Oncol Relationship Between PTEN and Angiogenesis of Esophageal Squamous Cell Carcinoma and the Underlying Mechanism. | ||
Bioorg Chem Design, synthesis and biological evaluation of anilide (dicarboxylic acid) shikonin esters as antitumor agents through targeting PI3K/Akt/mTOR signaling pathway. | ||
Chin Med Integrated metabolomics, network pharmacology and biological verification to reveal the mechanisms of Nauclea officinalis treatment of LPS-induced acute lung injury |












